Abstract
Epidermal growth factor receptors (EGFR) are over-expressed in many different types of cancer, thus, are logical targets for both diagnosis and therapy. Antibodies and antibody fragments targeting the extracellular EGF receptor and small molecules targeting the intracellular tyrosine kinase (TK) part of EGFR have been developed as possible diagnostic EGFR imaging agents. Recently, a 12-amino acid peptide, GE11, was identified using phage display screening to have high affinity for EGFR (Kd=22nM). Reported in vitro and in vivo characteristics of GE11 suggest that positron-labeled GE11 may be a useful PET imaging agent in selecting patients with EGFR-rich tumors who can most benefit from anti- EGFR therapy. To enable the exploration of this possibility, positron emitting [64Cu]Cu-NOTA-Bn-GE11 was prepared for further evaluation as PET EGFR imaging agent.
Keywords: Epidermal growth factor receptor (EGFR), GE 11, cancer, PET imaging, GE11-Bn-NOTA, Radiochemistry, MRI Scans
Current Radiopharmaceuticals
Title: Synthesis of [64Cu]Cu-NOTA-Bn-GE11 for PET Imaging of EGFR-Rich Tumors
Volume: 5 Issue: 1
Author(s): Onofre T. DeJesus
Affiliation:
Keywords: Epidermal growth factor receptor (EGFR), GE 11, cancer, PET imaging, GE11-Bn-NOTA, Radiochemistry, MRI Scans
Abstract: Epidermal growth factor receptors (EGFR) are over-expressed in many different types of cancer, thus, are logical targets for both diagnosis and therapy. Antibodies and antibody fragments targeting the extracellular EGF receptor and small molecules targeting the intracellular tyrosine kinase (TK) part of EGFR have been developed as possible diagnostic EGFR imaging agents. Recently, a 12-amino acid peptide, GE11, was identified using phage display screening to have high affinity for EGFR (Kd=22nM). Reported in vitro and in vivo characteristics of GE11 suggest that positron-labeled GE11 may be a useful PET imaging agent in selecting patients with EGFR-rich tumors who can most benefit from anti- EGFR therapy. To enable the exploration of this possibility, positron emitting [64Cu]Cu-NOTA-Bn-GE11 was prepared for further evaluation as PET EGFR imaging agent.
Export Options
About this article
Cite this article as:
T. DeJesus Onofre, Synthesis of [64Cu]Cu-NOTA-Bn-GE11 for PET Imaging of EGFR-Rich Tumors, Current Radiopharmaceuticals 2012; 5 (1) . https://dx.doi.org/10.2174/1874471011205010015
DOI https://dx.doi.org/10.2174/1874471011205010015 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nuclear Imaging of Prostate Cancer with Gastrin-Releasing-Peptide- Receptor Targeted Radiopharmaceuticals
Current Pharmaceutical Design Current Protein-based Anti-angiogenic Therapeutics
Mini-Reviews in Medicinal Chemistry Aptamers: Selection, Modification and Application to Nervous System Diseases
Current Medicinal Chemistry Identification of Disease States and Response to Therapy in Humans by Utilizing the Biomarker EGFR for Targeted Molecular Imaging
Current Protein & Peptide Science Targeting Tumors with Small Molecule Peptides
Current Cancer Drug Targets Codon Swapping of Zinc Finger Nucleases Confers Expression in Primary Cells and <i>In Vivo</i> from a Single Lentiviral Vector
Current Gene Therapy Anticancer Agents Derived from Natural Products
Mini-Reviews in Medicinal Chemistry The Transcription Factor ETS-1: Its Role in Tumour Development and Strategies for its Inhibition
Mini-Reviews in Medicinal Chemistry Cannabinoids as Analgesic Agents: Evidence from In Vivo Studies
Current Neuropharmacology GPR55 and its Interaction with Membrane Lipids: Comparison with Other Endocannabinoid-Binding Receptors
Current Medicinal Chemistry Nanotechnology and Brain Tumors Drug Delivery
Recent Patents on Nanomedicine Malignant Glioma In Vitro Models: On the Utilization of Stem-like Cells
Current Cancer Drug Targets Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy
Current Cancer Drug Targets Detection and Specific Targeting of Hypoxic Regions within Solid Tumors: Current Preclinical and Clinical Strategies
Current Medicinal Chemistry Molecular Aspects of FKBP51 that Enable Melanoma Dissemination
Current Molecular Pharmacology The Monoaminergic Tripartite Synapse: A Putative Target for Currently Available Antidepressant Drugs
Current Drug Targets Polyphenols: Biological Activities, Molecular Targets, and the Effect of Methylation
Current Molecular Pharmacology Post-Wortmannin Era: Novel Phosphoinositide 3-Kinase Inhibitors with Potential Therapeutic Applications
Current Enzyme Inhibition Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry Propolis Extract Regulates microRNA Expression in Glioblastoma and Brain Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry